Ximelagatran is more effective than warfarin in preventing thrombotic complications after total knee replacement (TKR), according to study findings presented here Monday. Moreover, unlike warfarin, ximelagatran does not require routine coagulation monitoring or dose adjustment.
Based on venographic analysis, two-thirds of patients who undergo TKR will develop deep venous thrombosis (DVT) if not treated with an anticoagulant. Although treatment with warfarin–the only oral anticoagulant approved for thrombotic prophylaxis in North America–can reduce DVT rates, up to 12% of treated patients will still develop proximal DVTs.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!